Biopharmaceutical company Gilead Sciences has completed the acquisition of YM BioSciences.
A Gilead subsidiary acquired all YM's outstanding common shares as per the terms of a plan of arrangement.
Thus, YM has become a wholly-owned subsidiary of Gilead.
YM shareholders will be entitled to receive $2.95 per common share in cash, and holders of warrants and stock options will be eligible for a cash payment equal to the difference between $2.95 and the exercise price of such warrant or stock option.
Source:
http://inwardinvestment.pharmaceutical-business-review.com/news/gilead-takes-over-ym-biosciences-110213
